Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized, Multicenter, Open Label Study to Compare the Efficacy and Tolerability of Pegylated Interferon-alpha-2 (PEG-IFN) to 'Low-dose' Interferon-alpha-2a in Patients With Malignant Melanoma in Stages IIA (T3a) - IIIB (AJCC 2002)

NCT00204529 is registered in ClinicalTrials.gov with University Hospital Tuebingen as lead sponsor.

NCT NCT00204529
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00204529 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized, Multicenter, Open Label Study to Compare the Efficacy and Tolerability of Pegylated Interferon-alpha-2 (PEG-IFN) to 'Low-dose' Interferon-alpha-2a in Patients With Malignant Melanoma in Stages IIA (T3a) - IIIB (AJCC 2002)
Lead sponsor
University Hospital Tuebingen
Phase
Phase 3
Overall status
Completed
Start date
October 31, 2004
Completion date
December 31, 2016
Enrollment
901 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

melanoma